

# The Thai Journal of Veterinary Medicine

---

Volume 42  
Issue 3 September, 2012

Article 1

---

9-1-2012

## Hand, Foot, and Mouth Disease

Juthatip Keawcharoen

Follow this and additional works at: <https://digital.car.chula.ac.th/tjvm>



Part of the [Veterinary Medicine Commons](#)

---

### Recommended Citation

Keawcharoen, Juthatip (2012) "Hand, Foot, and Mouth Disease," *The Thai Journal of Veterinary Medicine*: Vol. 42: Iss. 3, Article 1.

Available at: <https://digital.car.chula.ac.th/tjvm/vol42/iss3/1>

This Editorial is brought to you for free and open access by the Chulalongkorn Journal Online (CUJO) at Chula Digital Collections. It has been accepted for inclusion in The Thai Journal of Veterinary Medicine by an authorized editor of Chula Digital Collections. For more information, please contact [ChulaDC@car.chula.ac.th](mailto:ChulaDC@car.chula.ac.th).

## Hand, Foot, and Mouth Disease

**Juthatip Keawcharoen**

Department of Veterinary Microbiology, Faculty of Veterinary Science,  
Chulalongkorn University, Bangkok, Thailand

Hand, foot, and mouth disease (HFMD) is a contagious disease, which affects young children predominantly aged under 5 years old, but can also occur in adults. The disease is characterized by maculopapule and erythema on hands, feet, mouth, and buttocks. The neurological disorders and cardiovascular disease were reported in severe cases (Robinson et al., 1958; Huang et al., 1999; Yan et al., 2000; Legay et al., 2007; Chen et al., 2008; Hong et al., 2012).

HFMD is caused by enteroviruses which belong to the genus Enterovirus in the family Picornaviridae. The enteroviruses are small, non-enveloped, single-stranded, positive-sense RNA viruses. The viruses are classified into four individual species, based on their molecular and biological properties, including Poliovirus serotypes 1 to 3 (PV); Coxsackievirus groups A and B (CAV, serotypes 1 to 22 and 24 and CBV, serotypes 1 to 6); Enterovirus (EV) serotypes 68 to 71, 73 to 107 and finally the Echovirus (ECHO) serotypes 1 to 7, 9, 11 to 21, 24 to 27 and 29 to 33 (Hyypia et al., 1997; Muir et al., 1998; Pallansch and Roos, 2007; Yamashita et al., 2010).

Coxsackie virus A 16 (CAV 16) and enterovirus 71 (EV 71) are the most common serotypes, which cause HFMD. However, more severe forms of the disease are always associated with EV 71. HFMD was initially reported in New Zealand in 1957 (Kamahora et al., 1985). CAV 16 was first isolated in Canada in 1958, while EV 71 was first recognized in the United States between 1969 and 1972 (Robinson et al., 1958; Schmidt et al., 1974). Since the 1970s, HFMD has widely spread to other continents, especially in the Asia-Pacific region including Thailand (McMinn, 2003). Based on the surveillance data, CAV 16 was the most frequently isolated strain during the 1970s and 1980s; however, EV 71 has replaced it since the 1990s (Chan et al., 2011).

HFMD has become a serious disease causing death in young children in Sarawak, Malaysia since 1997 (Chan et al., 2011), in Taiwan since 1998 (Wu et al., 1999), in Singapore since 2000 (Chan et al., 2003), in India since 2003 (Sasidharan et al., 2005), in China

since 2008 (Yang et al., 2009) and in Vietnam since 2011 (WHO, 2012). In April 2012, 78 Cambodian children suffered from a severe form of HFMD and 54 deaths were reported (Joint press release between the Ministry of Health Kingdom of Cambodia and the World Health Organization, 2012).

The disease is spread through direct contact with infectious viruses via respiratory secretions, blister fluids and stool of infected patients. The virus can be detected in the stool and pharynx of infected persons several days before onset of clinical signs and can be shed via the stool for several weeks (Wang et al., 2011). HFMD has a short incubation period of 3 to 6 days. Most clinical signs are asymptomatic or mild. Early symptoms begin with low-grade fever, cough, and a sore mouth and throat leading to malaise and loss of appetite. After the first symptoms, the exanthema begins as small red spots or papules with blisters that commonly become ulcer. The lesions usually develop inside the mouth including buccal mucosa, hard palate, surfaces of the cheeks, gums and tongue, on palms of hands and soles of the feet. The lesions may also appear on the buttocks and genitalia (Batirbaygil and Altay, 1988; Jennifer and Antoinette; 1999; Russo et al., 2006; Choi et al., 2011). The pattern of HFMD rashes caused by CAV 16 differs from that caused by EV 71. The vesicles seen in infections caused by CAV 16 are usually larger than those observed in EV 71 infections. However, the rashes originated from EV 71, which are frequently found on the trunk and limbs, are more common and more petechial (Chen et al., 2008).

In some cases, HFMD may cause severe complications including myoclonic seizure, motor weakness, tremor, nystagmus, brainstem encephalitis, aseptic meningitis, poliomyelitis-like paralytic disease, opsoclonus-myoclonus syndrome and benign intracranial hypertension. Some cases show paroxysmal supraventricular tachycardia, pulmonary edema and pulmonary hemorrhage following sudden death due to cardiopulmonary failure (Fu et al., 2004; Chen et al., 2008; Cho et al., 2010; Choi et al., 2011; Hu et al., 2012).

Aside from the clinical manifestation, HFMD can be diagnosed by isolating the viruses from patients. Cell lines such as human rhabdomyosarcoma cells (RD Cells) and African green monkey kidney cells (Vero cells) have been widely used for CAV 16 and EV 71 isolation. For virus identification and serological analysis, neutralization test, reverse transcription-polymerase chain reaction (RT-PCR), sequencing, and immunofluorescence assay can be used to identify the viruses and antibodies against the viruses in clinical specimens (WHO, 2011).

There is no specific treatment for the disease. The general supportive and symptomatic therapy is necessary to control viral spread and prevent the disease complication. Topical analgesics such as benzylamine mouthwash or spray, choline salicylate gel or lidocaine gel can be used to relieve pain (MHRA, 2009; Muppa et al., 2011). Recently, low-level laser therapy has been applied for treating painful oral ulcers (Toida et al., 2003). Fever can be treated with antipyretics. Additionally, the usefulness of intravenous immunoglobulin has shown some potency in HFMD cases (Chan et al., 2003). However, in case of no common complications most patients recover without medical treatment in 7 to 10 days (Thomas, 2009).

There is currently no vaccine available for HFMD. Good personal and environmental hygiene and the avoidance of contact with infected individuals are necessary to protect from the disease (McMINN, 2003).

### References

- Batirbaygil, Y. and Altay, N. 1988. Hand foot and mouth disease. *J Islam Acad Sci.* 1(1): 17-19.
- Chan, K.P., Goh, K.T., Chong, C.Y., Teo, E.S., Lau, G. and Ling, A.E. 2003. Epidemic hand, foot and mouth disease caused by human enterovirus 71, Singapore. *Emerg Infect Dis.* 9(1): 78-85.
- Chan, Y-F., Sam, I-C., Wee, K-L. and Abubakar, S. 2011. Enterovirus 71 in Malaysia: A decade later. *Neurol Asia.* 16(1): 1-15.
- Chen, K.T., Lee, T.C., Chang, H.L., Yu, M.C. and Tang, L.H. 2008. Human enterovirus 71 disease: clinical features, epidemiology, virology, and management. *Open Epidemiol J.* 1(1): 10-16.
- Cho, H.Y., Lee, N.Y., Lee, H., Kim, H.S., Seo, J.W., Hong, Y.M., Lee, S.J., Lee, S.W., Cheon, D.S., Hong, J.Y., Kang, B.H., Kim, J.H. and Kim, K.H. 2010. Enterovirus 71-associated hand, foot and mouth diseases with neurologic symptoms, a university hospital experience in Korea, 2009. *Korean J Pediatr.* 53(5): 639-643.
- Choi, C.S., Choi, Y.J., Choi, U.Y., Han, J.W., Jeong, D.C., Kim, H.H., Kim, J.H. and Kang, J.H. 2011. Clinical manifestations of CNS infections caused by enterovirus type 71. *Korean J Pediatr.* 54(1): 11-16.
- Fu, Y.C., Chi, C.S., Chiu, Y.T., Hsu, S.L., Hwang, B., Jan, S.L., Chen, P.Y., Huang, F.L. and Chang, Y. 2004. Cardiac complications of enterovirus rhombencephalitis. *Arch Dis Child.* 89: 368-373.
- Hu, P., Hou, S., Du, P.F., Li, J.B. and Ye, Y. 2012. Paroxysmal supraventricular tachycardia in an infant with hand, foot, and mouth disease. *Ann Dermatol.* 24(2): 200-202.
- Huang, C.C., Liu, C.C., Chang, Y.C., Chen, C.Y., Wang, S.T. and Yeh, T.F. 1999. Neurologic complications in children with enterovirus 71. *N Engl J Med.* 341(13): 936-943.
- Hyypia, T., Hovi, T., Knowles, N.J. and Stanway, G. 1997. Classification of enteroviruses based on molecular and biological properties. *J Gen Virol.* 78: 1-11.
- Jennifer, C.H. and Antoinette, F.H. 1999. Hand-foot-and-mouth disease. In: Fitzpatrick's *Dermatology in General Medicine.* 5th ed. I.M. Freedberg and A.Z. Eisen (eds) New York: McGraw-Hill. 2403-2407.
- Kamahora, T., Itagaki, A., Hattori, N., Tsuchie, H. and Kurimura, T. 1985. Oligonucleotide fingerprint analysis of Coxsackievirus A10 isolated in Japan. *J Gen Virol.* 66: 2627-2634.
- Legay, F., Lévêque, N., Gacouin, A., Tattevin, P., Bouet, J., Thomas, R. and Chomel, J.J. 2007. Fatal Coxsackievirus A-16 pneumonitis in adult. *Emerg Infect Dis.* 13(7): 1084-1086.
- McMinn, P.C. 2003. Enterovirus 71 in the Asia-Pacific region: An emerging cause of acute neurological disease in young children. *Neurol J Southeast Asia* 8: 57-63.
- MHRA. 2009. Oral salicylate gels: Not for use in those younger than age 16 years. *Drug Safety Update.* 2(11): 4-5.
- Muir, P., Kammerer, U., Korn, K., Mulders, M.N., Poyry, T., Weissbrich, B., Kandolf, R., Cleator, G.M. and van Loon, A.M. 1998. Molecular typing of enteroviruses: Current status and future requirements. *Clin Microbiol Rev.* 11(1): 202-227.
- Muppa, R., Bhupatiraju, P., Duddu, M. and Dandampally, A. 2011. Hand, foot and mouth disease. *J Indian Soc Pedod Prev Dent.* 29(2): 165-167.
- Pallansch, M.A. and Roos, R. 2007. Enteroviruses: Polioviruses, Coxsackieviruses, Echoviruses, and newer enteroviruses. In *Fields Virology*, 5th ed, D.M. Knipe and P.M. Howley (eds). Philadelphia: Lippincott Williams & Wilkins. 839-893.
- Robinson, C.R., Doane, F.W. and Rhodes, A.J. 1958. Report of an outbreak of febrile illness with pharyngeal lesions and exanthem: Toronto, Summer 1957—Isolation of group A Coxsackie virus. *Can Med Assoc J.* 79(8): 615-621.
- Russo, D.H., Luchs, A., Machado, B.C., Carmona, R.C. and Timenetsky, M.C.S. 2006. Echovirus 4 associated to hand, foot and mouth disease. *Rev Inst Med trop S Paulo.* 48(4): 197-199.
- Sasidharan, C.K., Sugathan, P., Agarwal, R., Khare, S., Lal, S. and Jayaram Paniker, C.K. 2005. Hand, foot and mouth disease in Calicut. *Indian J Pediatrics.* 72: 17-21.
- Schmidt, N.J., Lennette, E.H. and Ho, H.H. 1974. An apparently new enterovirus isolated from patients with disease of the central nervous

- system. *J Infect Dis* 129: 304-309.
- Thomas, J. 2009. Hand-foot-and-mouth disease - An overview. *e-J Indian Soc Teledermatology*. 3(4): 1-5.
- Toida, M., Watanabe, F., Goto, K. and Shibata, T. 2003. Usefulness of low-level laser for control of painful stomatitis in patients with hand-foot-and-mouth disease. *J Clin Laser Med Surg*. 21(6): 363-367.
- Wang, J-F., Guo, Y-S., Christakos, G., YANG, W-Z., Liao, Y-L., Li, Z-J., Li, X-Z., Lai, S-J. and Chen, H-Y. 2011. Hand, foot and mouth disease: Spatiotemporal transmission and climate. *Int J Health Geogr*. 10(25): 1-10.
- World Health Organization. 2011. A Guide to Clinical Management and Public Health Response for Hand, Foot and Mouth Disease (HFMD). <http://www.wpro.who.int/publications/docs/GuidancefortheclinicalmanagementofHFMD.pdf>
- World Health Organization. 2012. Hand, foot and mouth disease (HFMD). [http://www.wpro.who.int/emerging\\_diseases/HFMD/en/index.html](http://www.wpro.who.int/emerging_diseases/HFMD/en/index.html)
- Joint press release between the ministry of health kingdom of Cambodia and the world health organization. 2012. Severe form of Hand, Foot and Mouth disease caused illnesses and deaths in majority of the children under recent investigation, Ministry of Health Cambodia concluded. <http://www.wpro.who.int/HFMDstory.pdf>
- Wu, T-N., Tsai, S-F., Li, S-F., Lee, T-F., Huang, T-M., Wang, M-L., Hsu, K-H. and Shen, C-Y. 1999. Sentinel surveillance for enterovirus 71, Taiwan, 1998. *Emerg Infect Dis*. 5(3): 458-460.
- Yamashita, T., Ito, M., Tsuzuki, H., Sakae, K. and Minagawa, H. 2010. Molecular identification of enteroviruses including two new types (EV-98 and EV-107) isolated from Japanese travellers from Asian countries. *J Gen Virol*. 91: 1063-1066.
- Yan, J-J., Wang, J-R., Liu, C-C., Yang, H-B. and Su, I-J. 2000. An outbreak of enterovirus 71 infection in Taiwan 1998: A comprehensive pathological, virological, and molecular study on a case of fulminant encephalitis. *J Clin Virol*. 17: 13-22.
- Yang, F., Ren, L., Xiong, Z., Li, J., Xiao, Y. and Zhao, R. 2009. Enterovirus 71 outbreak in the People's Republic of China in 2008. *J Clin Microbiol*. 47: 2351-2352.
- Zhou, H., Guo S-Z., Zhou, H., Zhu, Y-F., Zhang, L-J. and Zhang, W. 2012. Clinical characteristics of hand, foot and mouth disease in Harbin and the prediction of severe cases. *Chin Med J*. 125(7): 1261-1265.

